Challenging the idea that older people with shorter life expectancies should rank lower in coronavirus immunization efforts, new UC Berkeley research shows that giving vaccine priority to those most at risk of dying from COVID-19 will save the maximum number of lives, and their potential or future years of life.
The findings, published today, Feb. 25, in the journal Proceedings of the National Academy of Sciences, address the ethical dilemma of who should be first in line for a limited supply of vaccine shots amid a contagion that so far has killed 500,000 in the United States and 2.4 million globally.
“Since older age is accompanied by falling life expectancy, it is widely assumed that means we’re saving fewer years of life,” said study lead author Joshua Goldstein, a UC Berkeley professor of demography.
“We show this to be mistaken,” he added. “The age patterns of COVID-19 mortality are such that vaccinating the oldest first saves the most lives and, surprisingly, also maximizes years of remaining life expectancy.”
Taking age and health risks into account, Goldstein, UC Berkeley demographer Kenneth Wachter and Bucknell University mathematician Thomas Cassidy conducted an analysis of life expectancy in the United States, Germany and South Korea in the face of the yearlong coronavirus pandemic.
They based their calculations on the number of lives potentially saved from being vaccinated, multiplied by the life expectancy of those vaccinated. For example, if 1 million vaccinations saved 1,000 lives, and those vaccinated people, on average, were projected to live another 20 years, the total number of years of life saved would be 20,000.
The mathematical arguments upon which they based their conclusion apply not just to a few countries, but generally around the globe, the researchers said.
“Allocating scarce COVID-19 vaccine doses involves many tradeoffs. However, a conflict between minimizing the count of deaths and maximizing remaining life is not one of them,” Goldstein said.
Since the approval of various COVID vaccines last fall, and their rollouts in December, a debate has been mounting over which groups to inoculate first, given limited vaccine supplies and, in many cases, chaotic distribution systems.
While some groups have argued that essential workers should take priority to keep health, education and economic systems up and running, others, such as the World Health Organization, have declined the “Years of Life Lost” criterion in ranking vaccine recipients due to older people’s disproportionately higher risk of death and the perception that such an approach would be discriminatory and disrespectful.
This latest study should assuage some of those concerns, researchers said.
“Our empirical analysis shows it is easier than thought to set such fears aside and to give vaccine priority to the oldest and those in the most vulnerable states of health,” according to the paper, which notes that COVID deaths rise exponentially with age.
The researchers found that the COVID death rate by age increased by about 11% per year of age in the United States, Germany and Korea. Moreover, they found that vaccinating people in their 90s would save three times as many lives as giving the same doses to people in their 80s.
“Before this study, it was suspected that there would be some intermediate age—not too old and not too young—which would maximize the benefit of a vaccine, in terms of person years of life saved,” Goldstein said. “But surprisingly, we show this is not the case.”
Demographers put COVID-19 death toll into perspective
More information:
Joshua R. Goldstein et al. Vaccinating the oldest against COVID-19 saves both the most lives and most years of life, Proceedings of the National Academy of Sciences (2021). DOI: 10.1073/pnas.2026322118
Provided by
University of California – Berkeley
Citation:
Prioritizing oldest for COVID-19 vaccines saves more lives, years of life (2021, February 26)
retrieved 1 March 2021
from https://medicalxpress.com/news/2021-02-prioritizing-oldest-covid-vaccines-years.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
